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Purpose: Since there is no effective tumor marker for human renal cell
carcinoma (RCC), searching for novel markers for detection and followup
has clinical implications. Recent studies showed that some speciﬁc che-
mokines may affect angiogenesis, growth, andmetastasis of RCC. However,
the expression and role of CXCL14 (BRAK) in RCCwere largely unknown. In
this study, we studied the expression and potential role of CXCL14 (BRAK)
in human RCC.
Materials and Methods: CXCL14 (BRAK) expression was determined by
RT-PCR and real-time PCR in 5 RCC cell lines, and by immunohistochem-
istry (IHC) in 64 pairs of RCC and adjacent normal tissues. Migration assay
was done by migration chamber and Western blotting in 4 RCC cell lines.
Results: RT-PCR and real-time PCR revealed that CXCL14 (BRAK) expres-
sion was signiﬁcantly increased in 4 RCC than in non-tumor (HK-2) cell
lines (P < 0.001). IHC study also showed that CXCL14 (BRAK) expression
was signiﬁcantly higher in RCC than in normal tissues (P < 0.001). In
histological classiﬁcation, CXCL14 (BRAK) expression was signiﬁcantly
higher in conventional RCC than in non-conventional RCC tissues
(P ¼ 0.03). However, CXCL14 (BRAK) expression was not statistically
associated with sex, nuclear grading, or TNM stage. In the migration assay,
it was found that CXCL14 (BRAK) up-regulation was associated with the
migration ability of 786-O cells in a dose-dependent manner.
Conclusion: CXCL14 (BRAK) up-regulation may be involved in the
tumorigenesis and migration of human RCC.
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Purpose: To study important long non-coding RNA (lncRNA) change in
neuroendocrine differentiation of prostate cancer.
Materials and Methods: LNCaP cells was treated by hypoxic culture and
repressor element-1 silencing transcription factor (REST) knockdown to
study neuroendocrine differentiation (NED). Autophagic pathway as
well as REST expression were studied in LNCaP and CWR22Rv1 cells.
Several important lncRNA was examined in NED prostate cancer by
qRT-PCR.
Results: NED in LNCaP was induced by hypoxic culture and knockdown of
REST. In addition, autophagy pathway was induced in LNCaP cells. REST
expression is inversely related to neuroendocrine differentiation. Among
the lncRNA studied, HOTAIR is decreased after NED induction.
Conclusions: NED in prostate cancer is induced by hypoxia and REST
knockdown. Autophagy pathway is involved in NED of prostate cancer.
Furthermore, HOTAIR is decreased after NED in prostate cancer. The rela-
tion of lncRNA including HOTAIR is further studied in human samples.
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detoxiﬁcation and antioxidation and may affect cancer development or
outcome. We hypothesized that genetic variation in the GSH pathway
might inﬂuence the clinical outcome of patients who have non-muscle
invasive bladder cancer (NMIBC).
Materials and Methods: A total of 114 single nucleotide polymorphisms
(SNPs) in 21 GSH pathway genes were genotyped in 414 NMIBC patients
treated with trans-urethral resection alone (TUR) and both TUR and
intravesical bacillus Calmette-Guerin instillation (BCG) therapy. The effect
of each SNP on time to recurrence was estimated using the multivariate
Cox proportional hazards model. Cumulative effect and survival tree an-
alyses were performed to determine the joint effect of unfavorable geno-
types on bladder cancer prognosis.
Results: Seven SNPs showed signiﬁcant associations with cancer recur-
rence in the TUR group and 15 SNPs showed signiﬁcant associations with
recurrence in the BCG group. The most signiﬁcant SNP in the TUR group
was rs3746162 in GPX4, whose variant genotype conferred a 5.4-fold
increased risk of recurrence when compared to wild type (hazard ratio
[HR] ¼ 5.43, 95% conﬁdence interval [CI] ¼ 2.19-13.46), while the most
signiﬁcant SNP in the BCG group was rs7265992 in GSS (HR ¼ 3.43, 95%
CI ¼ 1.56-7.56). The risk of recurrence increased with the number of un-
favorable genotypes in both groups.
Conclusion: Genetic variants in GSH pathway may inﬂuence cancer
recurrence in NMIBC patients receiving curative treatment.
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Purpose: Most parts of urinary tracts, including renal pelvis, ureter,
bladder, and urethra, are covered by urothelial cells. Infection, urolithiasis,
malignancy, trauma, and even autoimmune diseases, such as retroperito-
neal ﬁbrosis, could cause urothelium deﬁciency or deﬁcit. Direct repair
with autologous tissues, such as foreskin, buccal mucosa, and gastroin-
testinal tracts might cause some complications due to different physio-
logical properties. Thus, in this study, we focused on cultivated urothelial
cells with proper biomaterial scaffold.
Materials and Methods: We successfully cultivated rat and bovine urothe-
lium with good cell viability and expression of the speciﬁc differentiation
marker, Uroplakin. As for biomaterial selection and comparison, we found
collagen type I is a good extracellular matrix, better than collagen IV, for
urothelium growth. And PDMS is a good synthetic polymer, better than EVAL
44, PLA, and chitosan, for urothelium growth and differentiation. Total 208
calcium oxalate urolithiasis patients and 105 healthy control subjects were
enrolled.Weanalyzed thesinglenucleotidepolymorphismsofTAP1andTAP2
gene using the polymerase chain reaction (PCR)-based restriction analysis.
Results: To achieve better cultivation efﬁciency, we adjusted medium
component and medium PH to ﬁnd the best cultivation circumstances.
Best cell adhesion was observed in the group, KSFM with Ca2+ supplement
than deﬁned KSFM and KSFM without Ca2+. As for medium PH, PH 8 is
suitable for bovine urothelium growth on TCPS, and PH 7.2 is suitable for
bovine urothelium growth on PDMS.
Conclusions: PDMS if a proper biomaterial for urothelium scaffold. We
found that bovine urothelium could maintain good viability and differ-
entiation status on PDMSmembrane.Wewould further fabricate 3D PDMS
scaffold, such as tubular PDMS scaffold for more applications in tissue
engineering of urothelium.
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